|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||96.34 - 116.93|
|52 Week Range||31.38 - 116.93|
|PE Ratio (TTM)||-22.22|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On a day stocks gyrated in response to Federal Reserve announcements, Bed Bath & Beyond fell sharply on earnings, and Alnylam Pharmaceuticals soared on a successful drug trial.
A new drug candidate that licences Arbutus Biopharma's proprietary technology passed an important milestone.
Alnylam gapped up Wednesday — to Ionis' detriment — after reporting positive results in a late-stage trial of a drug to treat a rare disease.